GENDICINE FOR
HEAD AND NECK CANCER
Gendicine — the world's first approved gene therapy — restores functional p53 tumour suppressor activity in head and neck squamous cell carcinoma, improving complete response rates when added to radiotherapy or chemoradiotherapy at specialist centres in China.
analyticsAt a Glance
- check_circleNMPA-approved in China since 2003 for head and neck squamous cell carcinoma (HNSCC)
- check_circlePhase III trial: 64% complete response rate with Gendicine + radiotherapy vs 19% with radiotherapy alone
- check_circleAdministered by direct intratumoral injection, typically once weekly for 8 weeks alongside radiotherapy
- check_circleAccessible to international patients at Chinese academic cancer centres via CancerFax
What Is Gendicine and Why Is It Used in Head and Neck Cancer?
Head and neck squamous cell carcinoma (HNSCC) is among the most p53-disrupted cancers in oncology — with TP53 mutations present in over 70% of cases. Gendicine delivers a functional copy of the wild-type p53 gene directly into tumour cells via a replication-deficient adenoviral vector, restoring the tumour suppressor signalling that drives cell cycle arrest and apoptosis.
“HNSCC is almost defined by p53 dysfunction — and Gendicine was specifically developed and first approved for this cancer type because of that direct mechanistic rationale.”
The p53 Rationale in HNSCC
More than 70% of head and neck squamous cell carcinomas carry TP53 mutations. Loss of p53 function allows tumour cells to evade DNA damage checkpoints and resist apoptosis — making radiotherapy and chemotherapy less effective. Gendicine directly addresses this by restoring functional p53 expression in tumour tissue.
How Gendicine Is Delivered
Gendicine is injected directly into the tumour — intratumorally — once per week, typically for 8 consecutive weeks, starting on the first day of radiotherapy. The adenoviral vector infects tumour cells at the injection site and delivers the p53 gene, which is expressed within 24–72 hours of injection.
Key Clinical Numbers
The pivotal Phase III trial and subsequent clinical series have established the following benchmarks for Gendicine in HNSCC.
- 64%Complete response rate: Gendicine + RTReported in the pivotal Phase III registration trial (Zhang et al., Hum Gene Ther 2003) for locally advanced HNSCC.
- 19%Complete response rate: RT aloneControl arm complete response in the same Phase III trial — a 3-fold improvement with the addition of Gendicine.
- >70%TP53 mutation frequency in HNSCCThe biological rationale for p53-targeted therapy in head and neck cancer is among the strongest of any tumour type.
- 8 wksStandard Gendicine treatment durationOne intratumoral injection per week for 8 weeks, administered concurrently with radiotherapy at the same treatment visit.
Clinical Efficacy: Trial Data
Published trial data from the NMPA registration study and subsequent Chinese institutional series support the efficacy of Gendicine combined with radiotherapy or chemoradiotherapy for HNSCC.
Phase III Registration Trial — Gendicine + RT vs RT Alone (HNSCC)
Source: Zhang SW et al., Hum Gene Ther. 2003;14(18):1781–1787
- Complete Response: Gendicine + RT64%
- Complete Response: RT alone19%
- Overall Response: Gendicine + RT93%
- Overall Response: RT alone79%
Post-Approval Series — Gendicine + Chemoradiotherapy (Locally Advanced HNSCC)
Pooled from post-approval Chinese institutional series; Wei et al. and affiliated centre data
- Complete Response: Gendicine + CRT72%
- 2-Year Progression-Free Survival58%
- Grade 3–4 Treatment-Related AEs18%
Eligibility and Treatment Considerations
The following criteria reflect the approved indication and standard patient selection used at Chinese centres administering Gendicine for HNSCC.
| Parameter | Criteria / Details |
|---|---|
| Approved indication | Head and neck squamous cell carcinoma (HNSCC) — all subsites including oral cavity, oropharynx, hypopharynx, larynx |
| Stage | Locally advanced (stage III–IV) disease is the primary population in registration and post-approval data; early stage with high-risk features also treated |
| p53 mutation status | Not required for eligibility — Gendicine is used regardless of TP53 mutation status, as vector-delivered p53 functions independently of endogenous status |
| Combination therapy | Standard use is concurrent with radiotherapy (60–70 Gy) or chemoradiotherapy (cisplatin-based); Gendicine monotherapy data are limited |
| Route of administration | Intratumoral injection — must be accessible under direct visualisation or image guidance; deep or base-of-skull lesions may require ENT endoscopic delivery |
| Treatment schedule | 1 × 10¹² viral particles per injection, once weekly for 8 weeks; dose may be divided across multiple injection sites in large tumours |
| Performance status | ECOG 0–2; poor performance status (ECOG 3–4) associated with higher toxicity and lower benefit; case-by-case assessment required |
| Prior treatment | Used in previously untreated locally advanced cases and in recurrent/refractory HNSCC after prior chemoradiotherapy |
Benefits vs Limitations
Gendicine offers a biologically targeted addition to standard chemoradiotherapy for HNSCC, but its clinical use requires specialist centre infrastructure and careful patient selection.
Benefits
- Dramatically improves complete response rate3-fold improvement in CR over radiotherapy alone in the registration trial — a clinically meaningful difference in a tumour type where complete pathological response strongly predicts long-term survival.
- Well-tolerated alongside chemoradiotherapyGendicine adds transient fever (38–39°C) in ~50% of patients but does not substantially increase haematologic toxicity, mucositis severity, or treatment interruptions versus CRT alone.
- Directly targets the dominant molecular driverTP53 mutation or dysfunction is present in >70% of HNSCC — the mechanistic rationale for p53 restoration in this disease is among the strongest of any gene therapy indication.
- Active in recurrent and refractory diseasePost-approval case series show activity in HNSCC recurring after prior chemoradiotherapy — a clinical situation with very limited standard options.
Limitations
- Intratumoral delivery limits to accessible lesionsGendicine must be injected directly into tumour tissue. Deep lesions, base-of-skull disease, or bulky nodal metastases may require ENT endoscopic injection — not available at all centres.
- Not approved outside ChinaGendicine is NMPA-approved in China but not EMA- or FDA-approved. International patients must travel to China to receive treatment, which is a significant logistical and financial commitment.
- Long-term OS benefit not established in RCTsWhile CR rates improve substantially, the effect on long-term overall survival has not been demonstrated in a large randomised phase III trial with survival as the primary endpoint.
- Requires co-administration with radiotherapyGendicine's clinical benefit is predominantly demonstrated in combination with radiotherapy. The radiation infrastructure must be co-located with or easily accessible from the centre administering Gendicine.
More from the Gendicine Resource Library
Continue exploring Gendicine — from the science of p53 to other cancer-specific applications and access pathways.
Frequently Asked Questions
Common questions from patients and families exploring Gendicine for head and neck cancer.
About Gendicine for HNSCC
Does my tumour need to have a p53 mutation to benefit from Gendicine?
No — this is a common misconception. Gendicine delivers a functional wild-type p53 gene into tumour cells regardless of the endogenous TP53 status. Even tumours without a detectable TP53 mutation may have dysfunctional p53 signalling through other mechanisms (MDM2 overexpression, viral E6 protein in HPV-positive HNSCC). In practice, Gendicine is administered without prior TP53 mutation screening at Chinese centres, based on the broad prevalence of p53 pathway dysfunction in HNSCC.
What does the injection feel like, and how long does each session take?
The intratumoral injection is performed using a fine-gauge needle under direct visualisation or endoscopic guidance. Patients typically experience mild local pressure and transient discomfort at the injection site. The injection itself takes 5–10 minutes. Approximately 50% of patients develop a low-grade fever (38–39°C) starting 2–6 hours after injection — this is an expected immune response to the adenoviral vector and resolves within 12–24 hours with paracetamol. The injection is usually given at the same visit as the radiotherapy fraction to minimise travel burden.
Is Gendicine effective for HPV-positive head and neck cancers?
HPV-positive oropharyngeal HNSCC has better overall prognosis than HPV-negative disease, and lower rates of TP53 mutation — the E6 viral protein degrades p53 by a different mechanism than direct mutation. The published Gendicine trials and series did not systematically stratify by HPV status, so direct comparative data are limited. Gendicine is used at Chinese centres for HPV-positive HNSCC, but the strongest mechanistic rationale and evidence base applies to HPV-negative, TP53-mutant disease. CancerFax can facilitate a specialist consultation to assess the relevance of HPV status to your specific case.
Can Gendicine be used after my cancer has recurred following prior chemoradiotherapy?
Yes — recurrent and refractory HNSCC is one of the settings where Gendicine is most commonly used in Chinese clinical practice, given the very limited standard options after failure of first-line chemoradiotherapy. Post-approval case series report objective responses in this setting. The combination partners in recurrent disease vary — some centres use Gendicine with salvage chemotherapy, others with re-irradiation if feasible, and others as part of a multimodal protocol. CancerFax can arrange a specialist review of your recurrence case to assess the best combination strategy.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Could Gendicine Be Right for Your Head and Neck Cancer?
CancerFax reviews your pathology, imaging, and treatment history to assess whether Gendicine is appropriate for your case — and connects you with specialist oncologists at approved Chinese centres experienced in administering p53 gene therapy for HNSCC.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.